Tuesday, September 20, 2016

BRIEF-Teva and regeneron announce global collaboration to develop Fasinumab

* To pay Regeneron $250 million upfront, share equally in

global commercial value, ongoing research & development costs of

about $1 billion

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)